Guadalajra, Mexico
Hitachi, Ibaraki
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Phase
3Span
457 weeksSponsor
CelgeneHitachi, Ibaraki
Recruiting
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
The protocol consists of 2 studies. Study 1 includes induction and maintenance treatment, and Study 2 includes only induction treatment. Each study has its own hypotheses and outcome measures that will be assessed independently.
Phase
3Span
321 weeksSponsor
Merck Sharp & Dohme LLCHitachi, Ibaraki
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
The protocol consists of 2 studies. Study 1 includes induction and maintenance treatment, and Study 2 includes only induction treatment. Each study has its own hypotheses and outcome measures that will be assessed independently.
Phase
3Span
284 weeksSponsor
Merck Sharp & Dohme LLCHitachi, Ibaraki
Recruiting
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase
3Span
440 weeksSponsor
Janssen Research & Development, LLCHitachi
Recruiting
1-5 of 5